1-2 of 2
Kaname Miyashita
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Pier Luigi Zinzani, Michael L. Wang, Sunita D. Nasta, Ewa Lech-Maranda, Yoshiaki Ogawa, Bita Fakhri, Bryone Kuss, Kaname Miyashita, Krish Patel, Catherine C. Coombs, Shuo Ma, Manish Patel, Minal A. Barve, Benoit Tessoulin, Anastasios Stathis, Won Seog Kim, Daisuke Ennishi, Daigo Hashimoto, Kensuke Kojima, Andrew D. Zelenetz, Jonathon B. Cohen, Julie M. Vose, Kami J. Maddocks, Talha Munir, Fangfang Sun, Faith Bian, Donald E. Tsai, Paolo Abada, Chan Y. Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 3026.
https://doi.org/10.1182/blood-2023-181309
Published: 2023
Journal Articles

Once-Weekly Subcutaneous Bortezomib Plus Oral Cyclophosphamide and Dexamethasone Therapy For Relapsed Or Refractory Multiple Myeloma

Yasushi Takamatsu, MD, PhD, Yutaka Imamura, MD, Tomonori Nakazato, MD, Naokuni Uike, MD, PhD, Kaname Miyashita, MD, Yoshio Saburi, MD, PhD, Naoki Harada, MD, Shuichi Ota, MD, PhD, Rie Imamura, MD, Toshihiro Miyamoto, MD
Journal: Blood
Blood (2013) 122 (21): 5382.
https://doi.org/10.1182/blood.V122.21.5382.5382
Published: 2013